HDAC Inhibitors

Discovery On Target

Location: Boston, MA
Date: November 2, 2010
Conference Website
Organizers: CHI

Meeting Summary

HDAC Inhibitors is part of CHI's International Discovery on Target event. This year's program focuses on tracking both the pre-clinical and clinical progress made by novel HDAC inhibitors and highlights the scientific discoveries made to better understand the cellular function of this drug target.

In addition, conference short courses*, dedicated exhibit hall hours, poster sessions and roundtable discussion groups will provide all participants ample opportunity to network, brain-storm and collaborate on various fronts.

Topics:

• What’s Next for HDAC Inhibitors - Better Combinations or Better Specificity?      
• Proteomic Approach to Define the Anti-Tumor Effects of an HDACi as Single Agent or in Combination Treatment    
• Augmenting the Efficacy of HDAC Inhibitors 
• Non-Peptide Macrocyclic Histone Deacetylase Inhibitors for Targeted Cancer Treatment
• New HDAC Inhibitors for Hematologic Malignancies     
• Understanding the Cellular Effects of HDACs
• Inherent Epigenetic Make-Up of Cancer Cells and their Predisposition to HDACi Sensitization        
• Function, Mechanism of Action, and Regulation of HDACs
• Pre-Clinical and Clinical Development of HDACi to Reverse Hormone Resistance in Breast Cancer     
• Clinical Update on Panobinostat     
• Targeting of HDAC Inhibitors to Monocytes and Macrophages: Potential in Cancer and Inflammatory Disease     
• Development of a Selective HDAC Inhibitor for Friedreich’s Ataxia